Literature DB >> 7200796

Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy.

K Landmark, S Sire, E Thaulow, J P Amlie, S Nitter-Hauge.   

Abstract

The haemodynamic effects of nifedipine, propranolol, and the combined administration of the two drugs were studied in 12 patients with hypertrophic obstructive cardiomyopathy. The combined administration of nifedipine and propranolol appeared to be superior to that of nifedipine alone. The spontaneous heart rate was reduced in most cases after nifedipine plus propranolol, and at atrial pacing the following results were obtained: left ventricular peak systolic pressure was reduced from 200 +/- 39 to 157 +/- 30 mmHg; a positive correlation was found between the pre-drug left ventricular end-diastolic pressure and the magnitude of reduction in left ventricular end-diastolic pressure; systolic blood pressure was reduced from 125 +/- 31 to 111 +/- 27 mmHg, and total peripheral resistance was reduced from 1403 +/- 307 to 1160 +/- 209 dyne s-1 cm-5. The combined administration reduced the resting left ventricular outflow gradient from 76 +/- 19 to 45 +/- 26 mmHg, while cardiac index was left unchanged. The effects on mean pulmonary arteriolar resistance and mean pulmonary arteriolar resistance and mean pulmonary capillary venous pressure were in most cases slight and insignificant. The results indicate an improved haemodynamic condition in patients with hypertrophic obstructive cardiomyopathy after the combined administration of nifedipine and propranolol: a treatment that might provide a new and useful alternative to already existing medication.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7200796      PMCID: PMC481196          DOI: 10.1136/hrt.48.1.19

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  37 in total

1.  Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy.

Authors:  P J Hubner; G M Ziady; G K Lane; T Hardarson; B Scales; C M Oakley; J F Goodwin
Journal:  Br Heart J       Date:  1973-11

Review 2.  Calcium-membrane interactions in the myocardium: effects of ouabain, epinephrine and 3',5'-cyclic adenosine monophosphate.

Authors:  A M Katz; D I Repke
Journal:  Am J Cardiol       Date:  1973-02       Impact factor: 2.778

Review 3.  The cardiomyopathies.

Authors:  J F Goodwin; C M Oakley
Journal:  Br Heart J       Date:  1972-06

4.  Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol.

Authors:  M D Flamm; D C Harrison; E W Hancock
Journal:  Circulation       Date:  1968-11       Impact factor: 29.690

5.  Cardiohemodynamic effects of BAY a 1040 in the dog.

Authors:  K Hashimoto; N Taira; S Chiba; K Hashimoto; M Endo
Journal:  Arzneimittelforschung       Date:  1972-01

6.  Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy.

Authors:  D A Swan; B Bell; C M Oakley; J Goodwin
Journal:  Br Heart J       Date:  1971-09

7.  The effect of noradrenaline on the calcium uptake of the sarcoplasmic reticulum.

Authors:  E A Shinebourne; M L Hess; R J White; J Hamer
Journal:  Cardiovasc Res       Date:  1969-04       Impact factor: 10.787

8.  Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade.

Authors:  L S Cohen; E Braunwald
Journal:  Circulation       Date:  1967-05       Impact factor: 29.690

9.  Membrane calcium current in ventricular myocardial fibres.

Authors:  G W Beeler; H Reuter
Journal:  J Physiol       Date:  1970-03       Impact factor: 5.182

10.  Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy.

Authors:  R H Edwards; A Kristinsson; D A Warrell; J F Goodwin
Journal:  Br Heart J       Date:  1970-03
View more
  5 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 3.  Pharmacologic treatment of hypertrophic cardiomyopathy: beta-blockade or calcium blockade or what?

Authors:  J F Goodwin
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 4.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 5.  Clinical decisions in the management of the cardiomyopathies.

Authors:  J F Goodwin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.